dexibuprofen
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
117
Go to page
1
2
3
4
5
July 16, 2026
A multivariate ANN-CCD integrative model using cellulose based polymers for the development of osmotically controlled push-pull dexibuprofen tablets and its predictive pharmacokinetic modeling.
(PubMed, Eur J Pharm Sci)
- "Physiologically Based Pharmacokinetic (PBPK) models for optimized formulations were developed using GastroPlusTM to simulate in vivo plasma profiles and compare with the real-time human pharmacokinetic data. The study demonstrates the promising role of biocompatible macromolecules in compressing the poorly compressible molecule, dexibuprofen, and modulating its release and in vivo pharmacokinetic performance from an osmotically controlled push-pull system for 12 h."
Journal • PK/PD data
June 17, 2026
Analyzing Spatial Variations in Molecular Mobility in Hydrated Amorphous Drug-Polymer Blends Using Fourier Transform Fluorescence Recovery After Photobleaching and Image Segmentation.
(PubMed, J Phys Chem B)
- "Stokes-Einstein estimates translated these values into local viscosities spanning ∼0.41 Pa·s (gel), 4.5 Pa·s (ibuprofen-rich), and 22 Pa·s (low-hydration ASD), highlighting pronounced microheterogeneity within the hydrated ASD matrix. Together, these results provide a quantitative, spatially explicit link between drug loading, phase morphology, local mobility, and macroscopic release, and establish segmented FT-FRAP as a practical tool for diagnosing failure mechanisms and guiding formulation of high-loading ASDs."
Journal
June 07, 2026
Network pharmacology identifies repurposable drugs targeting host pathways across the oral-gut-lung axis.
(PubMed, Naunyn Schmiedebergs Arch Pharmacol)
- "Centrality-weighted drug prioritization consistently ranked indomethacin, ibuprofen, dexibuprofen, mesalazine, and cannabidiol as high-confidence repositioning candidates for densely connected host networks. Enrichment analyses demonstrated convergence on immune signaling pathways, cytoskeletal remodeling, PPAR signaling, and focal adhesion networks. This study presents a reproducible and generalizable network medicine workflow that formalizes interactome construction, multi-metric centrality assessment, and composite drug ranking in a unified analytical framework. The proposed strategy enables the systematic identification of conserved host regulatory vulnerabilities and repositionable therapeutics across infectious and chronic inflammatory diseases, thereby advancing host-directed therapeutic discovery in translational biomedical informatics."
Journal • Inflammation • CAV1 • CDC42 • PPARG • RHOA
April 23, 2026
Dose escalation study for targeted radionuclide therapy with [¹⁶¹Tb]Tb-SibuDAB in mCRPC - PROGNOSTICS Phase Ib study
(SNMMI 2026)
- P1 | "SibuDAB is a novel PSMA-targeted albumin-binding peptidomimetic developed at PSI, consisting of a urea-based PSMA ligand conjugated to (S)-ibuprofen to prolong blood circulation and enhance tumor uptake and retention... Initial results from the first two cohorts of the PROGNOSTICS Phase Ib study demonstrate a favorable safety profile of [¹⁶¹Tb]Tb-SibuDAB with early signs of antitumor activity. Comprehensive dosimetry, subacute toxicity, and efficacy data from treated patients will be presented."
P1 data • Castration-Resistant Prostate Cancer • Dental Disorders • Genito-urinary Cancer • Leukopenia • Neutropenia • Prostate Cancer • Solid Tumor • Thrombocytopenia • Xerostomia • CTCs
May 19, 2026
Pharmacokinetics, dosing exposure and safety of oral ibuprofen in Chinese preterm neonates with patent ductus arteriosus: preliminary report.
(PubMed, BMJ Paediatr Open)
- P=N/A | "The recommended dosage regimen for Chinese preterm neonates with hsPDA may be insufficient to achieve targeted therapeutic exposure. Importantly, our study indicated that even at a relatively high dose, drug exposure might remain within the therapeutic window. Moreover, we observed a higher conversion ratio of R-IBU to S-IBU in these neonates than in adults. The use of ibuprofen may be associated with an elevated risk of jaundice in preterm infants."
Journal • PK/PD data • Cardiovascular
April 23, 2026
Single-center Randomized Controlled Trial of Postoperative Analgesia in Facial Plastic Surgery
(ChiCTR)
- P=N/A | N=90 | Sponsor: Plastic Surgery Hospital, Chinese Academy of Medical Sciences; Plastic Surgery Hospital, Chinese Academy of Medical Sciences
New trial
March 25, 2026
Antifebrile effects of dexibuprofen suppository on children with high fever.
(PubMed, Pak J Pharm Sci)
- "Dexibuprofen suppository provides rapid and effective antipyresis with better safety in pediatric emergency settings."
Journal • Retrospective data • Pediatrics
March 18, 2026
Retraction notice to "Local infiltration of the surgical wounds with levobupivacaine, dexibuprofen, and norepinephrine to reduce postoperative pain: A randomized, vehicle-controlled, and preclinical study" [Biomed. Pharmacother. 92 (2017) 459-467].
(PubMed, Biomed Pharmacother)
- No abstract available
Journal • Preclinical • Pain
March 13, 2026
Simultaneous rapid structure identification and accurate quantitation of chiral drugs based on a home-built polarized Raman microscope.
(PubMed, Opt Lett)
- "The experimental results of the coefficients of determination (R2) are 0.957 for racemic ibuprofen and 0.988 for (S)-ibuprofen, and their root mean square error of prediction (RMSEP) values are 0.126% and 0.049%, respectively. These preliminary results give a hint that polarized Raman spectroscopy (PRS) is a powerful non-destructive analytical tool for drug applications. These preliminary results give a hint that polarized Raman spectroscopy (PRS) is a powerful non-destructive analytical tool for drug applications."
Journal
March 02, 2026
Enhanced Anticancer Activity of Ibuprofen and 2'-Hydroxy-2,3,5'-trimethoxychalcone-Linked Polymeric Micelles in HeLa Cells.
(PubMed, ACS Omega)
- "We synthesized a polymeric micelle formulation incorporating (S)-ibuprofen ((S)-IP) and 2'-hydroxy-2,3,5'-trimethoxychalcone (DK143), termed (S)-IP-DK143 NP...The combination of pH-sensitive polymeric micelles and chalcone-based chemotherapy represents a promising approach for cervical cancer treatment. Further preclinical and clinical studies are warranted to validate its potential as an injectable anticancer formulation."
Journal • Cervical Cancer • Gynecologic Cancers • Hematological Disorders • Leukopenia • Oncology • Solid Tumor
February 27, 2026
Impact of Drug Hydrophilicity on Transdermal Delivery by Nanoemulsions.
(PubMed, Pharmaceutics)
- "Viscosity values covered broad ranges (3-9532 mPa·s for salbutamol; 13.4-9759 mPa·s for ibuprofen), with salbutamol generating an extended high-viscosity domain at 50% (w/w) surfactant and ibuprofen showing a narrower viscosity maximum at 30-40% surfactant...High surfactant levels suppressed permeation for both APIs, but the dominant positive drivers differed: balanced oil-water ratios for salbutamol and hydration-dependent diffusional resistance for ibuprofen. These findings demonstrate that API polarity and interfacial portioning behavior decisively govern NE performance, providing a framework for rational tailoring of oil-surfactant-water ratios to maximize transdermal delivery efficiency."
Journal
February 13, 2026
Double Salts and Racemate in Mefloquine-Ibuprofen and Mefloquine-Ketoprofen Systems. A Structural and Thermochemical Analysis.
(PubMed, Chirality)
- "Using a drug-drug approach, we have investigated the crystallization behavior of Mefloquine (Mf), a racemic antimalarial drug, in combination with enantiopure (S)-ibuprofen and (S)-ketoprofen, as well as their racemic forms. On the other hand, the racemate with ketoprofen and the double salt with ibuprofen are the most soluble structures, suggesting that they are more stable systems than their counterparts. These findings support the view that double salt formation in such systems results from structural mimicry of racemates, emphasizing the challenges of predictable enantiomeric resolution and the importance of understanding structure-property relationships in chiral crystallization."
Journal • Infectious Disease
January 15, 2026
Ultrasensitive Fluorescent Detection of Urinary Trypsin for Early Pancreatic Disease Diagnosis: Toward Smartphone-Assisted Analysis.
(PubMed, Chem Asian J)
- "Its clinical applicability was further validated in the presence of acute pancreatitis (AP)-inducing factors, including aspirin, ibuprofen, dexibuprofen, acetaminophen, 6-mercaptopurine, as well as ethanol and its metabolites (acetaldehyde and acetate). In addition, urine samples were successfully analyzed using a smartphone-integrated fluorescence detection system, highlighting its practicality and clinical potential for early pancreatic disease diagnosis."
Journal • Pancreatitis • Targeted Protein Degradation
January 07, 2026
The Stereoselective Pharmacokinetics of Ibuprofen Enantiomers in Mice, Guinea Pigs, and Rats.
(PubMed, Chirality)
- "A chiral LC-MS/MS method was employed to simultaneously determine (R)-(-)-ibuprofen and (S)-(+)-ibuprofen in trace whole blood samples (5 μL)...Conversion rates calculated from R-IBU and S-IBU concentrations following racemic IBU administration exhibited significant interspecies differences: 54.9 ± 5.6% (rats), 76.6 ± 5.3% (mice), and 65.6 ± 6.7% (guinea pigs). In contrast, no significant species differences were observed when conversion rates were derived from S-IBU concentrations after administration of individual enantiomers (R-IBU and S-IBU), yielding values of 65.9 ± 6.5%, 76.8 ± 21.2%, and 66.3 ± 14.4% for rats, mice, and guinea pigs, respectively."
Journal • PK/PD data • Preclinical
October 21, 2025
Origin of phase relative stability and phase transformation in an S-ibuprofen-nicotinamide cocrystal.
(PubMed, Acta Crystallogr C Struct Chem)
- "The determination of the crystallographic structure of this metastable form allowed an explanation of the main mechanisms at the origin of the relative stability of the two forms of the S-ibuprofen-nicotinamide cocrystals. This also made it possible to explain the transition mechanism between the two forms with temperature."
Journal • CDKN1A
September 13, 2025
Theoretical Examination on the Chiral Separation Mechanism of Ibuprofen on Cellulose Tris(4-methylbenzoate).
(PubMed, Molecules)
- "Our results demonstrated that, based on the optimized geometry using the ML-T2C-ELG method, the complexation energy of S-ibuprofen with CMB obtained at B3LYP-D3(BJ)/6-311G(d) level is more negative than that of R-ibuprofen, which is caused by the greater hydrogen bonding and π-π stacking interactions between CMB and S-ibuprofen...Moreover, the ML-T2C-ELG method was found to be valuable for optimizing the geometries of such flexible and large systems, which allows for a more accurate description of interactions between soft polymers and small molecules when coupled with the docking simulation. It is anticipated that this study can provide beneficial insights for future optical resolution mechanisms of other chiral drugs."
Journal
September 12, 2025
Sustainable D-Glucose-based ibuprofen ionic liquids/salts for anti-inflammatory applications.
(PubMed, Bioorg Chem)
- "Cytotoxicity and anti-inflammatory evaluations were performed on the synthesized GSIS/GSIL-Ibu in comparison to ibuprofen utilizing the mouse fibroblast cell line 3T3-L1. Formulations of enantiomerically pure S-ibuprofen demonstrated superior anti-inflammatory efficacy compared to racemic ibuprofen formulations."
Journal
August 07, 2025
Evaluate the safety and efficacy of dexibuprofen in improving fever symptoms in children aged 6 months to 3 years old Multi center post marketing clinical research plan
(ChiCTR)
- P4 | N=586 | Recruiting | Sponsor: The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University
New P4 trial • Infectious Disease • Respiratory Diseases
August 07, 2025
Efficacy and Safety of Dexibuprofen in the Treatment of Acute Infection-Induced Fever in Children
(ChiCTR)
- P4 | N=135 | Not yet recruiting | Sponsor: children's hospital of fudan university; children's hospital of fudan university
New P4 trial • Infectious Disease • Respiratory Diseases
August 07, 2025
A comparative study of dexibuprofen or celecoxib for neurosurgical over-the-counter and postoperative analgesia
(ChiCTR)
- P4 | N=126 | Recruiting | Sponsor: Sanbo Brain Hospital of Capital Medical University; Sanbo Brain Hospital of Capital Medical University
New P4 trial
July 16, 2025
Gradient, reversed-phase HPLC method for simultaneous determination of chemical and enantiomeric impurities of dexibuprofen in a single run.
(PubMed, J Chromatogr A)
- "In this work, a gradient reversed-phase HPLC method is presented for the simultaneous determination of four potential chemical impurities in dexibuprofen, as well as its chiral isomer, (R)-ibuprofen. Furthermore, the stability and robustness of the gradient system were confirmed by consistent performance over one hundred consecutive injections. Following regulatory validation guidelines, the developed HPLC method was effectively applied for the quality assessment of commercially available pharmaceutical formulations."
Journal
June 06, 2025
Efficacy and Safety of Dexibuprofen Oral Suspension for Fever Treatment in Children with Acute Lower Respiratory Tract Infections: A Multicenter, Randomized Controlled Trial
(ChiCTR)
- P4 | N=552 | Not yet recruiting | Sponsor: Department of Pediatrics, Xijing Hospital, the Fourth Military Medical University, Xi'an, China; Shaanxi International Medical Exchange Promotion Asso
New P4 trial • Infectious Disease • Respiratory Diseases
June 06, 2025
Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients.
(PubMed, J Nucl Med)
- "225Ac-labeled (S)-ibuprofen-diaminobutyric acid-PSMA (SibuDAB) is a novel, albumin-binding compound in prostate-specific membrane antigen (PSMA)-targeted α-therapy of prostate cancer...Only limited signs of xerostomia were observed after the treatment. 213Bi generated by recoil is rapidly distributed into urine after application of [225Ac]Ac-SibuDAB."
Journal • Dental Disorders • Genito-urinary Cancer • Hematological Disorders • Oncology • Prostate Cancer • Solid Tumor • Thrombocytopenia • Xerostomia
June 05, 2025
Near-Field Terahertz Nanoscopy Spatially Resolves Chiral Drug-Cell Interactions: Toward Precision Intracellular Pharmacology.
(PubMed, Anal Chem)
- "We systematically analyzed morphological and biochemical compositional differences between control cells and those treated with RS-ibuprofen, (R)-(-)-ibuprofen, and (S)-(+)-ibuprofen...Quantitative analysis of spectral intensity differences within nuclear regions (p < 0.001), based on single-frequency imaging and clustering analyses at characteristic THz peak frequencies, provided direct evidence of drug-induced heterogeneity. These findings establish a novel paradigm for mapping drug-cell interactions at the nanoscale, conceptualizing these processes as spatially encoded phenomena, thereby advancing the field of subcellular chiral pharmacology."
Journal
June 05, 2025
Anticancer Activity of Phospholipid-Dexibuprofen Conjugates Loaded in Nanostructured Lipid Carriers.
(PubMed, Int J Nanomedicine)
- "Antiproliferative assays confirmed enhanced activity of synthesized products and their increased accumulation in cancer cells. This study describes the synthesis of new conjugates of DXI and phospholipids and their nanotechnological formulations for potential use in cancer therapy."
Journal • Oncology
1 to 25
Of
117
Go to page
1
2
3
4
5